Pharma Mar S.A./€PHM
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Pharma Mar S.A.
Pharma Mar S.A. is a biopharmaceutical company based in Madrid, Spain, specializing in the research, development, and commercialization of marine-derived drugs. The company's core focus is on oncology, where it develops and produces antitumor drugs. Its product portfolio includes compounds such as Yondelis, Aplidin, and Zepzelca, each targeting various forms of cancer. Founded in 1986, Pharma Mar is part of the pharmaceutical group Zeltia. The company leverages its unique access to marine biodiversity to create differentiated products, positioning itself distinctively within the pharmaceutical industry. Pharma Mar operates globally, with a significant foothold in both European and international markets.
Ticker
€PHM
Sector
Primary listing
BME
Employees
500
Headquarters
Website
Pharma Mar S.A. Metrics
BasicAdvanced
€1.5B
19.47
€4.30
0.45
€0.80
0.96%
Price and volume
Market cap
€1.5B
Beta
0.45
52-week high
€92.98
52-week low
€64.36
Average daily volume
1K
Dividend rate
€0.80
Financial strength
Current ratio
3.019
Quick ratio
2.201
Long term debt to equity
14.566
Total debt to equity
19.622
Dividend payout ratio (TTM)
18.60%
Interest coverage (TTM)
24.69%
Profitability
EBITDA (TTM)
68.735
Gross margin (TTM)
94.46%
Net profit margin (TTM)
33.87%
Operating margin (TTM)
27.42%
Effective tax rate (TTM)
-25.71%
Revenue per employee (TTM)
€440,000
Management effectiveness
Return on assets (TTM)
10.19%
Return on equity (TTM)
32.59%
Valuation
Price to earnings (TTM)
19.471
Price to revenue (TTM)
6.592
Price to book
5.83
Price to tangible book (TTM)
5.86
Price to free cash flow (TTM)
33.357
Free cash flow yield (TTM)
3.00%
Free cash flow per share (TTM)
2.51
Dividend yield (TTM)
0.96%
Growth
Revenue change (TTM)
26.61%
Earnings per share change (TTM)
188.68%
3-year revenue growth (CAGR)
4.08%
10-year revenue growth (CAGR)
1.34%
3-year earnings per share growth (CAGR)
16.35%
10-year earnings per share growth (CAGR)
28.21%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharma Mar S.A. stock?
Pharma Mar S.A. (PHM) has a market cap of €1.5B as of March 19, 2026.
What is the P/E ratio for Pharma Mar S.A. stock?
The price to earnings (P/E) ratio for Pharma Mar S.A. (PHM) stock is 19.47 as of March 19, 2026.
Does Pharma Mar S.A. stock pay dividends?
Yes, the Pharma Mar S.A. (PHM) stock pays dividends to shareholders. As of March 19, 2026, the dividend rate is €0.8 and the yield is 0.96%. Pharma Mar S.A. has a payout ratio of 18.6% on a trailing twelve-month basis.
When is the next Pharma Mar S.A. dividend payment date?
The next Pharma Mar S.A. (PHM) dividend payment date is unconfirmed.
What is the beta indicator for Pharma Mar S.A.?
Pharma Mar S.A. (PHM) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.